Surface Injectable Contract Manufacturing Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2030

The global surface injectable contract manufacturing market was valued at USD 14.8 billion in 2022, and a CAGR of 8.1% is expected during the forecast period. Unlike therapeutic drugs, injectable have the ability to bypass the innate defense mechanism of the body, ensuring higher efficiency of therapeutic drugs. Growing demand for cell therapy and gene therapy has driven the demand for surface injectable in the market significantly. Operational efficiency and cost reduction are the key features of surface injectable. The increasing prevalence of chronic diseases like cancer, diabetes, neurological disorders, infectious disorders, and cardiovascular disorders is driving growth in the market.

Growth Drivers

Growing pipelines of injectable drugs, including biologics, cell, and gene therapies, which require specialized sterile manufacturing environments. These innovative therapies, particularly for diseases like cancer and autoimmune disorders, drive the demand for contract manufacturing. As biologics and biosimilars become more common, their complexities necessitate expertise in sterile manufacturing. Contract manufacturers are playing a crucial role in meeting these production requirements, particularly in cancer and chronic disease treatments.

Increasing demand for outsourcing their manufacturing to contract manufacturing organizations to streamline operations and reduce costs is driving growth in the market. Advances in production technology, especially for complex injectable formulations, are also driving growth in the market significantly. Increasing investment by companies in novel techniques to meet stringent regulatory standards is also driving growth in the market.

Segmentation

By Molecules Type

·         Biologics

·         Small Molecules

By Therapeutic Applications

·         Cancer

·         Diabetes

·         Cardiovascular disease

·         Neurological Disorders

·         Infectious Disorders

·         Muscoskeletal Disorders

·         Others

Route of Administration

·         Subcutaneous

·         Intravenous

·         Intramuscular

·         Others

By End-User

·         Pharmaceutical Companies

·         Biopharmaceutical Companies

·         Others

Regional Outlook

·         Asia Pacific

·         North America

·         Latin America

·         Middle East and Africa

·         Europe

Surface Injectable Contract Manufacturing Market by Therapeutic Application

On the basis of therapeutic application, the surface injectable contract manufacturing market is segmented into cancer, diabetes, neurological disorders, cardiovascular disorders, infectious diseases, muscoskeletal diseases, and others. Many cancer therapies involve biologics and novel treatments, which often require sterile injectable formats to maintain drug stability, effectiveness, and precise delivery. Sterile injectable are crucial for delivering advanced oncology treatments, like monoclonal antibodies, immunotherapies, and cell-based therapies.

Increasing global incidence of cancer is a significant driver of demand for injectable therapies. For example, in regions like North America and especially in Canada, the number of cancer patients is increasing significantly. Growing burden fuels the need for contract manufacturers to produce specialized sterile injectable drugs. Pharmaceutical companies involved in cancer drug development increasingly outsource the production of these complex therapies to contract manufacturing organizations to optimize efficiency and manage costs. Regulatory approvals of new cancer treatments, especially biologics and biosimilars, are accelerating. These therapies often require sophisticated sterile manufacturing processes, which drives further demand for contract manufacturing services. Neurological disorders such as Alzheimer’s and Parkinson’s are also driving the demand in the market significantly. Parkinson disease is very common these days, and some rare diseases like OPCA are also contributing to the market growth significantly.

Surface Injectable Contract Manufacturing Market by Molecules Type Segmentation

On the basis of the type, the surface injectable contract manufacturing market is segmented into biologics and small molecules. Biologics is emerging as the leading segment because biologics, such as monoclonal antibodies, vaccines, and gene therapies, are complex molecules that require specialized manufacturing markets. Demand for biologics has increased due to their ability to deal with chronic diseases like cancer, diabetes, and neurological disorders in an effective manner. Biologics often need sterile injectable formats to ensure stability and precise administration.

Development of pipelines for biologics has grown significantly. Trend is driving the demand for contract manufacturing organizations. The rise of biosimilars, which are generic versions of biologics, is another key factor. Due to their complexity, biologics require stringent manufacturing processes, which pharmaceutical companies prefer to outsource to specialized CMOs. This demand for high-quality production facilities is making biologics the dominant segment in the market. Growing demand for cell therapy and gene therapy has driven the demand for surface injectable in the market significantly. Operational efficiency and cost reduction are the key features of surface injectable.

Regional Outlook

On the basis of the regions, the surface injectable contract manufacturing market is segmented into 5 regions: Asia Pacific, North America, Europe, the Middle East and Africa, and Europe. North America is the leading segment due to well-established healthcare infrastructure and the presence of major market players in the region. Well-established biotech manufacturing infrastructure includes advanced sterile manufacturing facilities and technologies needed for producing complex injectable products like biologics and biosimilars. Companies like Baxter, Catalent, and Vetter Pharma have specialized capabilities in sterile injectable manufacturing.

Additionally, the high level of research and development spending in the region supports innovation in drug development. North America has a growing burden of chronic diseases like cancer, diabetes, and neurological disorders. Neurological disorders like Alzheimer and Parkinson disease are playing a crucial role in the expansion of the market. Asia Pacific is also witnessing significant growth due to increasing population in emerging economies like China, South Korea, and Japan. Increasing disposable income, rapidly growing urbanization, and industrialization are driving growth in the market. The increasing number of cancer patients due to lifestyle imbalances in the region is the key factor behind the growth in the region.

Pharmaceutical companies in the region are the key drivers in the market significantly. The European market is witnessing significant growth due to the increasing number of chronic disease patients in Germany, France, Russia, the U.K., and Nordic countries. Increasing growth in research and development activities is driving growth in the European market. The presence of some key players in the European market is driving growth in the market. Rising awareness among the people about chronic diseases like cancer, diabetes, and neurological disorders is driving growth in the market. Rising disposable income and research and development activities in health endeavors are driving growth in the market. Latin American and Middle East regions are witnessing slow growth during the forecast period.

Key Players

·         Abbvie

·         Biopharma Group

·         Biotechnique

·         BirgiMefar Group

·         Brooks Laboratories

·         Curidas A.S.

·         Evonic

·         Mithra CDMO

·         Pfizer

·         Polfa Tarchomin

·         Prague Scientific

·         Other Players